ReviewNeuro-oncology2022
T lymphocytes as dynamic regulators of glioma pathobiology.
Review in Neuro-oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 51 citations in OpenAlex.
- Brain barriers at the crossroads of glioma immune surveillance and immunotherapy response.Nature reviews. Cancer · 2026Review
- Integrated transcriptomic network analysis reveals shared immunogenomic regulators between glioma and type 2 diabetes, highlighting VCAN as a prominent marker.Scientific reports · 2026Article
- Ostreae Testa enhances anti-tumor immunity by activating T cells via antigen-presenting cell stimulation.Cell communication and signaling : CCS · 2026Article
- Targeting immunosuppressive network in glioblastoma: Emerging strategies to overcome immunodeficiency and enhance therapeutic efficacy.Acta pharmaceutica Sinica. B · 2026Review
- Variability of the Immunosuppressive Properties of Glioma Cell Lines.Bulletin of experimental biology and medicine · 2026Article
- Immunotherapy in central nervous system tumors.International journal of surgery (London, England) · 2025Review
- Analysis of the efficacy and influencing factors of double-dose furmonertinib for advanced EGFR ex20ins non-small cell lung cancer.Journal of translational medicine · 2025Article
- Charting the single-cell and spatial landscape of IDH-wild-type glioblastoma with GBmap.Neuro-oncology · 2025Article
- Advances in Cellular Immune Theranostic Approaches for Glioblastoma: Current Trends and Future Directions.Cancer innovation · 2025Review
- Insights of immune cell heterogeneity, tumor-initiated subtype transformation, drug resistance, treatment and detecting technologies in glioma microenvironment.Journal of advanced research · 2025Review
- Early Detection of Glioma: Investigating Inflammatory Markers (CRP), Kidney, and Liver Function.CNS & neurological disorders drug targets · 2025Article
- Engineering neuroimmune regulation: biomaterial and nanotechnology platforms for neuropathology diagnosis and targeted immunomodulation.Frontiers in immunology · 2025Review
- Human single cell RNA-sequencing reveals a targetable CD8Nature communications · 2024Article
- Advances in CAR-T therapy for central nervous system tumors.Biomarker research · 2024Review
- Glioma immune microenvironment composition calculator (GIMiCC): a method of estimating the proportions of eighteen cell types from DNA methylation microarray data.Acta neuropathologica communications · 2024Article
- Review
- Extracellular Matrix Structure and Interaction with Immune Cells in Adult Astrocytic Tumors.Cellular and molecular neurobiology · 2024Review
- Applications of artificial intelligence in the analysis of histopathology images of gliomas: a review.Npj imaging · 2024Review
- Glioblastoma microenvironment-from biology to therapy.Genes & development · 2024Review
- Harnessing innate immune pathways for therapeutic advancement in cancer.Signal transduction and targeted therapy · 2024Review
Corrections and comments
- Commented on by
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
The brain tumor microenvironment contains numerous distinct types of nonneoplastic cells, which each serve a diverse set of roles relevant to the formation, maintenance, and progression of these central nervous system cancers. While varying in frequencies, monocytes (macrophages, microglia, and myeloid-derived suppressor cells), dendritic cells, natural killer cells, and T lymphocytes represent the most common nonneoplastic cellular constituents in low- and high-grade gliomas (astrocytomas). Although T cells are conventionally thought to target and eliminate neoplastic cells, T cells also exist in other states, characterized by tolerance, ignorance, anergy, and exhaustion. In addition, T cells can function as drivers of brain cancer growth, especially in low-grade gliomas. Since T cells originate in the blood and bone marrow sinuses, their capacity to function as both positive and negative regulators of glioma growth has ignited renewed interest in their deployment as immunotherapeutic agents. In this review, we discuss the roles of T cells in low- and high-grade glioma formation and progression, as well as the potential uses of modified T lymphocytes for brain cancer therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.